Abidoye, O., Shibuki, T., Pirozzi, A., Hoyek, C., Okano, N., Junior, P. L. S. U., … Bekaii-Saab, T. (2025). 332P Impact of chemoimmunotherapy (CIO) vs chemotherapy (CT) alone in patients with HRD-positive and HRD-negative biliary tract cancers (BTC): A multicenter retrospective survival analysis. In Annals of Oncology (Vol. 36, pp. S130–S130). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.05.347

Abidoye, O., T. Shibuki, A. Pirozzi, C. Hoyek, N. Okano, PLS Uson Junior, M. F. B. Teixeira, et al. “332P Impact of chemoimmunotherapy (CIO) vs chemotherapy (CT) alone in patients with HRD-positive and HRD-negative biliary tract cancers (BTC): A multicenter retrospective survival analysis.” In Annals of Oncology, 36:S130–S130. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.05.347.

Abidoye O, Shibuki T, Pirozzi A, Hoyek C, Okano N, Junior PLSU, et al. 332P Impact of chemoimmunotherapy (CIO) vs chemotherapy (CT) alone in patients with HRD-positive and HRD-negative biliary tract cancers (BTC): A multicenter retrospective survival analysis. In: Annals of Oncology. Elsevier BV; 2025. p. S130–S130.

Abidoye, O., et al. “332P Impact of chemoimmunotherapy (CIO) vs chemotherapy (CT) alone in patients with HRD-positive and HRD-negative biliary tract cancers (BTC): A multicenter retrospective survival analysis.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S130–S130. Crossref, doi:10.1016/j.annonc.2025.05.347.

Abidoye O, Shibuki T, Pirozzi A, Hoyek C, Okano N, Junior PLSU, Teixeira MFB, Ahn D, Sonbol MB, Wu C, Yoshino T, Imai-Sumida M, Morizane C, Bando H, Nakamura Y, Fujisawa T, Strickler JH, Borad MJ, Ikeda M, Bekaii-Saab T. 332P Impact of chemoimmunotherapy (CIO) vs chemotherapy (CT) alone in patients with HRD-positive and HRD-negative biliary tract cancers (BTC): A multicenter retrospective survival analysis. Annals of Oncology. Elsevier BV; 2025. p. S130–S130.